

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3236564

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
BAKULESH MAFATLAL KHAMAR	12/31/2013
RAJIV INDRAVADAN MODI (EXECUTOR OF NOW DECEASED INVENTOR INDRAVADAN AMBALAL MODI)	12/31/2013
RECEIVING PARTY DATA	
Name:	CADILA PHARMACEUTICALS LTD.
Street Address:	CADILA CORPORATE CAMPUS
Internal Address:	SARKHEJ-DHOLKA RD., BHAT
City:	AHMEDABAD
State/Country:	INDIA
Postal Code:	382210
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	14628534
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	DOCKETING@BURNSLEV.COM
Correspondent Name:	BURNS & LEVINSON LLP
Address Line 1:	125 SUMMER ST
Address Line 4:	BOSTON, MASSACHUSETTS 02110
ATTORNEY DOCKET NUMBER:	43939-111DIV
NAME OF SUBMITTER:	SHAHID HASAN
SIGNATURE:	/SHAHID HASAN/
DATE SIGNED:	02/23/2015
Total Attachments: 5	
source=CADILA-111DIV_ASSIGNMENT#page1.tif	
source=CADILA-111DIV_ASSIGNMENT#page2.tif	
source=CADILA-111DIV_ASSIGNMENT#page3.tif	
source=CADILA-111DIV_ASSIGNMENT#page4.tif	

ASSIGNMENT

WHEREAS, we, **Indravadan Ambalal Modi**, Cadila Corporate Campus, Sarkhej-Dholka Rd. Bhat, India; and **Bakulesh Mafatlal Khamar**, a resident of Cadila Corporate Campus, Sarkhej-Dholka Rd, Bhat, India (hereinafter referred to collectively as "Assignors"): have jointly made an invention entitled **PHARMACEUTICAL COMPOSITION FOR TREATING CANCER**, which claims priority to **INDIAN** Application Serial No. 92/MUM/2011, filed on January 11, 2011, and for which an application for a United States Patent was filed on July 10, 2013 and accorded U.S. Patent Application Serial No. 13/978,923.

WHEREAS, **CADILA PHARMACEUTICALS, LTD**, a corporation organized and existing under the laws of **INDIA**, having its principal place of business at **AHMEDABAD, INDIA** (hereinafter referred to as "Assignee"), is desirous of acquiring right, title and interest in said invention.

NOW, THEREFORE, in consideration of One Dollar (\$1.00), and other good and valuable consideration, the receipt of which is hereby acknowledged, Assignors by these presents, do sell, assign and transfer to Assignee, Assignors' entire right, title and interest, for the United States of America and its possessions and territories and for all foreign countries, in and to said invention, including all rights of priority created and conferred by any treaty or international convention which is available in connection with said invention, including the right to apply for patent rights, U.S. or foreign, and in any continuations, continuations-in-part, divisions, substitutes, renewals, reissues or other applications filed in the U.S. or abroad (including multinational filing arrangements of all kinds), and in any U.S. or foreign patents issued on any such applications and reissues, extensions and renewals thereof, to be held and enjoyed by Assignee, for its own use and behalf and for its successors and assigns, to the full ends of the terms or extended terms for which any Letters Patents or the like may be granted, as fully and entirely as the same would have been held by Assignors had this sale, assignment and transfer not been made.

Assignors hereby authorize and request the Commissioner of Patents of the United States, and any official of any country or countries (including multinational filing arrangements of all kinds), whose duty it is to receive and/or examine applications for patents or similar intellectual/industrial property, issue patents or other evidence or forms of intellectual/industrial property protection on applications as aforesaid, to issue the same to Assignee, its successors and assigns, in accordance with the terms of this instrument.

Assignors covenant with Assignee, its successors, assigns, and legal representatives that Assignors have full right to convey the entire interest herein assigned,

and that Assignors have not executed any agreement in conflict herewith and will not execute any agreement or conveyance in conflict herewith.

Assignors further covenant and agree to communicate to Assignee, its successors, legal representatives and assigns, any facts known to Assignors respecting said invention, and testify in any legal proceeding, sign all lawful papers, including, without limitation, application papers, assignments, powers of attorney, declarations, and other instruments, execute all divisional, continuing, substitute, reissue, renewal and foreign applications, make all truthful oaths, declarations and statements, and generally do everything reasonably requested of Assignors by Assignee, or its successors or assigns to aid Assignee, its successors or assigns, to obtain, enforce and/or exploit said invention.

Executed this 31 day of December, 2013.

.....
Rajiv Indravadan Modi
(Executor of now-deceased inventor
Indravadan Ambalal Modi)

As Evidenced by Certified True Copy of The Resolution Passed By The Board Of Directors of Cadila Pharmaceuticals Limited at their meeting held on December 8, 2012 at the Registered Office of the Company (Attached herewith as Exhibit A)

Khamar B.M

.....
Bakulesh Mafatlal Khamar

ASSIGNMENT

WHEREAS, we, Indravadan Ambalal Modi, Cadila Corporate Campus, Sarkhej-Dholka Rd, Bhat, India; and Bakulesh Mafatlal Khamar, a resident of Cadila Corporate Campus, Sarkhej-Dholka Rd, Bhat, India (hereinafter referred to collectively as "Assignors"); have jointly made an invention entitled PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, which claims priority to INDIAN Application Serial No. 92/MUM/2011, filed on January 11, 2011, and for which an application for a United States Patent was filed on July 10, 2013 and accorded U.S. Patent Application Serial No. 13/978,923.

WHEREAS, CADILA PHARMACEUTICALS, LTD, a corporation organized and existing under the laws of INDIA, having its principal place of business at AHMEDABAD, INDIA (hereinafter referred to as "Assignee"), is desirous of acquiring right, title and interest in said invention.

NOW, THEREFORE, in consideration of One Dollar (\$1.00), and other good and valuable consideration, the receipt of which is hereby acknowledged, Assignors by these presents, do sell, assign and transfer to Assignee, Assignors' entire right, title and interest, for the United States of America and its possessions and territories and for all foreign countries, in and to said invention, including all rights of priority created and conferred by any treaty or international convention which is available in connection with said invention, including the right to apply for patent rights, U.S. or foreign, and in any continuations, continuations-in-part, divisions, substitutes, renewals, reissues or other applications filed in the U.S. or abroad (including multinational filing arrangements of all kinds), and in any U.S. or foreign patents issued on any such applications and reissues, extensions and renewals thereof, to be held and enjoyed by Assignee, for its own use and behalf and for its successors and assigns, to the full ends of the terms or extended terms for which any Letters Patents or the like may be granted, as fully and entirely as the same would have been held by Assignors had this sale, assignment and transfer not been made.


Assignors hereby authorize and request the Commissioner of Patents of the United States, and any official of any country or countries (including multinational filing arrangements of all kinds), whose duty it is to receive and/or examine applications for patents or similar intellectual/industrial property, issue patents or other evidence or forms of intellectual/industrial property protection on applications as aforesaid, to issue the same to Assignee, its successors and assigns, in accordance with the terms of this instrument.

Assignors covenant with Assignee, its successors, assigns, and legal representatives that Assignors have full right to convey the entire interest herein assigned, and that Assignors have not executed any agreement in conflict herewith and will not execute any agreement or conveyance in conflict herewith.

Attorney Docket No. 43939-00111 (Cadila Pharmaceuticals Ltd.)
Application No.: 13/978,923


Assignors further covenant and agree to communicate to Assignee, its successors, legal representatives and assigns, any facts known to Assignors respecting said invention, and testify in any legal proceeding, sign all lawful papers, including, without limitation, application papers, assignments, powers of attorney, declarations, and other instruments, execute all divisional, continuing, substitute, reissue, renewal and foreign applications, make all truthful oaths, declarations and statements, and generally do everything reasonably requested of Assignors by Assignee, or its successors or assigns to aid Assignee, its successors or assigns, to obtain, enforce and/or exploit said invention.

Executed this 31st day of December, 2013.



Rajiv Indravadan Modi
(Executor of now-deceased inventor
Indravadan Ambalal Modi)

As Evidenced by Certified True Copy of The Resolution Passed By The Board Of Directors of Cadila Pharmaceuticals Limited at their meeting held on December 8, 2012 at the Registered Office of the Company (Attached herewith as Exhibit A)



Bakulesh Mafatlal Khamar

CERTIFIED TRUE COPY OF THE RESOLUTION PASSED BY THE BOARD OF DIRECTORS OF CADILA PHARMACEUTICALS LIMITED AT THEIR MEETING HELD ON DECEMBER 8, 2012 AT THE REGISTERED OFFICE OF THE COMPANY

The Board was informed that Mr. Indravadan A. Modi, Chairman and Managing Director has expired on 26th November, 2012. Dr. Rajiv I Modi, Managing Director, is the Legal Heir, Legal Representative and Executor of late Mr. Indravadan A. Modi. The late Mr. Indravadan A. Modi was Inventor to various patent applications made in India and worldwide.

"RESOLVED THAT the Board hereby authorizes Dr. Rajiv I Modi, Managing Director being the Legal Heir, Legal Representative and Executor to sign on behalf of late Mr. Indravadan A. Modi on all existing patent related applications and future patent related matters..

RESOLVED FURTHER THAT a copy of this resolution be forwarded to the Competent Authorities in India and worldwide and they are requested to act thereupon."

Certified True Copy
For Cadila Pharmaceuticals Limited


(Shreyas Parikh)
Company Secretary

